Mark Jacobson Sells 4,517 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock

Key Points

• COO Mark Jacobson sold 4,517 shares on May 4 at an average price of $227.94 for roughly $1.03M, a transaction the company says reduced his position by 50% (SEC filing).
• Strong revenue but earnings miss: Axsome reported 1Q net product revenue of $191.2M (up ~57% YoY) driven by AUVELITY and SUNOSI, yet GAAP EPS was a ($1.26) loss versus a roughly ($0.85) consensus, widening losses and raising near‑term profitability concerns.
• Analyst sentiment improving: Several firms raised price targets (examples include Mizuho $310, Jefferies $275, Oppenheimer $280) and coverage is largely positive (consensus target ~$251.89) while shares traded around $223 with above‑average volume.

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) COO Mark Jacobson sold 4,517 shares of the company's stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $227.94, for a total transaction of $1,029,604.98. Following the transaction, the chief operating officer owned 4,517 shares in the company, valued at $1,029,604.98. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Axsome Therapeutics Stock Performance

Axsome Therapeutics stock traded down $0.64 during mid-day trading on Tuesday, reaching $223.06. 1,019,532 shares of the company traded hands, compared to its average volume of 882,597. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.55 and a quick ratio of 1.48. Axsome Therapeutics, Inc. has a fifty-two week low of $96.09 and a fifty-two week high of $234.29. The company has a market capitalization of $11.47 billion, a price-to-earnings ratio of -59.80 and a beta of 0.59. The firm's fifty day moving average is $171.73 and its two-hundred day moving average is $163.34.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its quarterly earnings results on Monday, May 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.41). The company had revenue of $191.20 million for the quarter, compared to analyst estimates of $191.10 million. Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 246.90%. The business's revenue for the quarter was up 57.4% on a year-over-year basis. On average, equities research analysts expect that Axsome Therapeutics, Inc. will post -1.05 earnings per share for the current fiscal year.

Axsome Therapeutics News Summary

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Very strong top-line growth — 1Q net product revenue of $191.2M, up ~57% YoY, driven by AUVELITY ($153.2M) and SUNOSI ($33.9M); this validates commercial traction for Axsome’s lead products. Axsome 1Q 2026 Financial Results
• Positive Sentiment: Multiple analyst price-target lifts today (notably Mizuho to $310, Wells Fargo to $255, Baird to $246, Morgan Stanley to $242) and continued “buy/outperform” coverage increase perceived upside and support near-term sentiment. Analyst Coverage & Price Target Moves
• Positive Sentiment: Pipeline and corporate catalysts remain in play — AUVELITY approval for agitation in Alzheimer’s, NDA submission for AXS‑12 (cataplexy), addition of AXS‑20 to the pipeline — these can drive medium/long-term upside. Business Update & Pipeline Highlights
• Neutral Sentiment: Management outreach: Axsome will participate in multiple investor conferences (BofA fireside chat, others) — useful for additional disclosure but timing/impact is uncertain. Investor Conference Participation
• Neutral Sentiment: Full earnings and call transcripts are available for deeper read-throughs; analysts and commentators are parsing sequential trends and guidance in detail. Earnings Call Transcript & Analysis
• Negative Sentiment: Earnings miss: GAAP EPS of ($1.26) vs. consensus (~$0.85 loss) — the wider loss and negative margins/ROE raise near-term profitability concerns despite revenue strength. Q1 Loss Widens; Revenues Jump (Zacks)
• Negative Sentiment: Some skepticism on sustainability — commentary notes sequential sales dips for key products and questions about achievability of management’s long‑term peak revenue targets, which could temper enthusiasm. Earnings Review & Skepticism (Seeking Alpha)

Analysts Set New Price Targets

AXSM has been the topic of a number of research reports. Jefferies Financial Group increased their price objective on shares of Axsome Therapeutics from $245.00 to $275.00 and gave the stock a "buy" rating in a research note on Monday. Needham & Company LLC set a $267.00 price objective on shares of Axsome Therapeutics and gave the stock a "buy" rating in a research note on Tuesday. Oppenheimer set a $280.00 price objective on shares of Axsome Therapeutics in a research note on Monday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Axsome Therapeutics in a research note on Monday, April 20th. Finally, TD Cowen reiterated a "buy" rating on shares of Axsome Therapeutics in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $251.89.

Institutional Trading of Axsome Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in Axsome Therapeutics by 6.0% during the third quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company's stock worth $507,739,000 after buying an additional 235,626 shares in the last quarter. Franklin Street Advisors Inc. NC purchased a new stake in Axsome Therapeutics during the fourth quarter worth $1,826,000. Stanley Laman Group Ltd. purchased a new stake in Axsome Therapeutics during the third quarter worth $2,125,000. Aberdeen Group plc boosted its holdings in Axsome Therapeutics by 15.5% during the third quarter. Aberdeen Group plc now owns 94,648 shares of the company's stock worth $11,495,000 after buying an additional 12,732 shares in the last quarter. Finally, TD Asset Management Inc boosted its holdings in Axsome Therapeutics by 107.7% during the third quarter. TD Asset Management Inc now owns 44,192 shares of the company's stock worth $5,367,000 after buying an additional 22,914 shares in the last quarter. 81.49% of the stock is owned by hedge funds and other institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome's pipeline includes several late-stage and approved product candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.